We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

17 hedge funds and large institutions have $1.83M invested in Rein Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $1.3M → $1.83M (+$527K)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.61% less ownership

Funds ownership: 23.14% → 22.53% (-0.61%)

11% less funds holding

Funds holding: 19 → 17 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.27%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
–
Increased
5
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$4.93K
2
UBS Group
UBS Group
Switzerland
+$1.94K
3
TRCT
Tower Research Capital (TRC)
New York
+$661
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$380
5
Wells Fargo
Wells Fargo
California
+$2

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$28.7K
2
HF
HRT Financial
New York
-$14K
3
William Blair & Company
William Blair & Company
Illinois
-$3.93K
4
HighTower Advisors
HighTower Advisors
Illinois
-$231
5
Bank of America
Bank of America
North Carolina
-$23
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$1.49M – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$98.5K +$380 +247 +0.5%
Vanguard Group
3
Vanguard Group
Pennsylvania
$72.4K -$28.7K -18,626 -32%
William Blair & Company
4
William Blair & Company
Illinois
$53.1K -$3.93K -2,550 -8%
KL
5
KCK Ltd
Bermuda
$40K – – –
HighTower Advisors
6
HighTower Advisors
Illinois
$34K -$231 -150 -0.8%
Renaissance Technologies
7
Renaissance Technologies
New York
$28K +$4.93K +3,200 +25%
TRCT
8
Tower Research Capital (TRC)
New York
$6.7K +$661 +429 +13%
JWA
9
JFS Wealth Advisors
Pennsylvania
$2.85K – – –
UBS Group
10
UBS Group
Switzerland
$2.43K +$1.94K +1,257 +1,257%
Morgan Stanley
11
Morgan Stanley
New York
$2.24K – – –
US Bancorp
12
US Bancorp
Minnesota
$2.24K – – –
BlackRock
13
BlackRock
New York
$338 – – –
Bank of America
14
Bank of America
North Carolina
$224 -$23 -15 -11%
IGWM
15
ICA Group Wealth Management
Colorado
$179 – – –
Wells Fargo
16
Wells Fargo
California
$43 +$2 +1 +4%
HF
17
HRT Financial
New York
– -$14K -11,671 Closed

RNTX Hedge Fund Activity: Q2 2023 in Review

17 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2023, worth a combined $1.83M — up 40% from $1.3M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RNTX and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $4.93K. The largest seller was Vanguard Group, cutting an estimated $28.7K.

  • 17 institutional investors held Rein Therapeutics (RNTX) as of Q2 2023, down from 19 in Q1 2023.
  • Funds reported $1.83M of Rein Therapeutics stock for Q2 2023, up 40% quarter-over-quarter.
  • 0 funds opened new Rein Therapeutics positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Rein Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $4.93K added.
  • The largest Rein Therapeutics seller in Q2 2023 was Vanguard Group, an estimated $28.7K sold.

Based on aggregated 13F filings for Q2 2023.